GSK said it now expects adjusted operating profit to increase between 13-15% for the year after it reported a rise in net profit in the third quarter, mainly due to the U.S. launch of its Arexvy vaccine.
GSK said it now expects adjusted operating profit to increase between 13-15% for the year after it reported a rise in net profit in the third quarter, mainly due to the U.S. launch of its Arexvy vaccine.